RheumNow’s expanded coverage of the #ACR2025 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

Singla et al. In secukinumab phase 3 trials, fungal (inc candida) infections uncommon. 5.51 for sec vs 3.39 for PBO per 100PY. @RheumNow #ACR25 Abstr#585 https://t.co/g78zUsxD5a

• https://x.com/RichardPAConway/status/1982476060890649026/photo/1

Schmidt et al. 2 year results of SELECT-GCA, upadacitinib in GCA. Remission 69% if upa continued vs 29% if stopped. 90% lower risk of flare, 1G less steroid @RheumNow #ACR25 Abstr#0776 #ACRBest https://t.co/MgRo7kIgIw

• https://x.com/RichardPAConway/status/1982475306330935638/photo/1

Not all inflammatory nasal lesions are vasculitis! Dr. Zacharek presents from the ENT perspective @RheumNow #ACR25 https://t.co/TJ4d56oBaJ

• https://x.com/Dr_Brian_MD/status/1982475138420650281/photo/1

Post-hoc PEXIVAS study, estimating risk of relapse from baseline variables Lotsa fancy stats, mostly corroborated known risk factors, but model predicted relapse reasonably well! Probably useful for approach to monitoring... mayyybe treatment? #ACR25 @RheumNow #Abstr0722 https://t.co/XI9y8KgDNR

• https://x.com/EBRheum/status/1982474802700140629/photo/1
• https://x.com/EBRheum/status/1982474802700140629/photo/1
• https://x.com/EBRheum/status/1982474802700140629/photo/1

Statins and SLE: To add or not to add? 💊 Abstract #0599: In an emulated target trial of patients with SLE, statin users vs non-users had significantly⬇️ risk of all-cause death in both ITT & per-protocol analyses. - No significant differences in MACE or ESKD. @RheumNow #ACR25

Mease et al. Sometimes perspective is all important! We worry about apremilast causing GI effects, anorexia, weight loss. Here we see reported benefits for weight loss and HbA1c. @RheumNow #ACR25 Abstr#581 https://t.co/CJjS0VZxWH

• https://x.com/RichardPAConway/status/1982474299413049770/photo/1

Tracking RA disease activity got a measurable boost in the VA: a 3-month multimodal rollout (feedback, EHR tools, just-in-time lists) raised DAM documentation up to 10%. Small structural changes, big data gains. @RheumNow #ACR25 Abstract#0221

Plenary 1: SELECT-GCA (RCT, UPA vs PLBO in GCA) Pts in remission re-randomized at wk52 Higher maintenance of remission in pts who continued UPA15 (69%) vs switchers from UPA15->PLBO (29%) Argues strongly for continuing tx in GCA for >1yr! @RheumNow #ACR25 Ab#0776 #ACRBest https://t.co/exmmIcpgbP

• https://x.com/EBRheum/status/1982473544505372756/photo/1
• https://x.com/EBRheum/status/1982473544505372756/photo/1

tRNA-derived RNA (tDR-1), circulating microbial RNA Associated w/ reduction in risk of RA conversion in asymptomatic CCP+ individuals (60 vs. 120+ ctrls), ‼️ tDR-1 alone over performs prediction model w/ smoking shared episode and RF w/ AUC 0.86 What is the mechanism? tDR-1 https://t.co/fuyk4NeOyA

• https://x.com/AurelieRheumo/status/1982473500922187877/photo/1
• https://x.com/AurelieRheumo/status/1982473500922187877/photo/1
• https://x.com/AurelieRheumo/status/1982473500922187877/photo/1

Ribeiro et al. Case series of combination bDMARD/tsDMARD in PsA from Toronto. 24 patients, median just over a year follow-up. Appear effective, especially for objective skin and joint measures. No major safety concerns but short follow-up to date. @RheumNow #ACR25 Abstr#565 https://t.co/Zk3odT2EX2

• https://x.com/RichardPAConway/status/1982473041276981274/photo/1

#0775 Higher circulating microbial small RNA tDR-1 linked to lower risk of developing RA in CCP3+ individuals (AUC 0.86). tDR-1 downregulates interferon-response genes in vitro, suggesting microbiome-mediated anti-inflammatory mechanism in RA pathogenesis. @RheumNow #ACR25

SLE & arthritis: Is there a difference? Abstract #0629: - Non-deforming (ND): 73% | Jaccoud’s: 19% | Rhupus: 8% - Vs ND, Rhupus had lower odds of type I IFN signature - Time to deformities: Jaccoud's ~2 yrs vs Rhupus ~5 yrs - RNP+ predictive of Jaccoud’s @RheumNow #ACR25

Why do some clinics excel at RA disease activity tracking while others struggle? In the VA, success came down to structure: RA-specific clinics, templates, and staff. Barriers? Time, missing labs, and workflow gaps. @RheumNow #ACR25 Abstract#0222

Managing lupus is complex. How do we ensure quality care? Abstract #0218 convened 8 focus groups: ✅ Support for patient navigators ⚠️ Barriers: low resources, staff turnover 💻 Solution: EHR outreach workflow to flag missed visits & labs @RheumNow #ACR25 https://t.co/BWaIMMEPit

• https://x.com/AkhilSoodMD/status/1982472035658826210/photo/1